Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"

被引：0
|
作者：
Jiang, Yanfang [1 ]
Zhang, Lei [2 ,3 ]
机构：
[1] First Hosp Jilin Univ, Genet Diag Ctr, Changchun, Peoples R China
[2] Med Res Ctr, Key Lab Digital Technol Med Diagnost Zhejiang Prov, Hangzhou, Peoples R China
[3] Nanjing Med Univ, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 09期
关键词：
D O I：
10.1016/j.jtho.2024.06.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e43 / e43
页数：1
相关论文
共 50 条
  • [31] Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
    Skoulidis, F.
    Li, B. T.
    Hochmair, M. J.
    Govindan, R.
    Vincent, M.
    Van der Wekken, A. J.
    Reguart Aransay, N.
    O'Byrne, K. J.
    Girard, N.
    Griesinger, F.
    Nishio, M.
    Hafliger, S.
    Lindsay, C.
    Reinmuth, N.
    Paulus, A.
    Papakotoulas, P.
    Obiozor, C.
    Nduka, C.
    Wang, Y.
    De Langen, A. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S830 - S831
  • [32] KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
    Lim, Tony Kiat Hon
    Skoulidis, Ferdinandos
    Kerr, Keith M.
    Ahn, Myung-Ju
    Kapp, Joshua R.
    Soares, Fernando A.
    Yatabe, Yasushi
    LUNG CANCER, 2023, 184
  • [33] A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
    Markman, B.
    Solomon, B.
    Nott, L. M.
    Roberts-Thomson, R.
    Hughes, B.
    Pavlakis, N.
    Davis, A.
    Brown, L. J.
    Parakh, S.
    Brungs, D.
    Bowyer, S. E.
    Nordman, I.
    Jennens, R.
    Warburton, L.
    Harris, S. J.
    Samuel, E.
    Ramanujam, S.
    Wang, A.
    Dumas, M.
    Gard, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1700 - S1700
  • [34] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [35] Prognostic implication of KRAS G12C mutation in a real-world KRAS mutated stage IV NSCLC cohort treated with immunotherapy in the Netherlands
    Noordhof, Anneloes L.
    Swart, Esther M.
    Damhuis, Ronald A. M.
    Hendriks, Lizza E. L.
    Kunst, Peter W. A.
    Aarts, Mieke J.
    Van Geffen, Wouter H.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [36] CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Font, E. F.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S29 - S29
  • [37] Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (vol 389, pg 2125, 2023)
    Fakih, Marwan G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (07): : 728 - 728
  • [38] KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro
    Mohn, Deanna
    Saiki, Anne Y.
    Achanta, Pragathi
    Stapper, Andres Plata
    Lipford, J. Russell
    Verma, Rati
    CANCER RESEARCH, 2023, 83 (07)
  • [39] KRAS G12C mutated NSCLC and bladder cancer xenografts treated with sotorasib and adagrasib in combination with mTOR inhibitors show improved antitumor activity of nab-sirolimus vs everolimus
    Hou, S.
    Nieva, J.
    Desai, N.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S58 - S59
  • [40] Oncogenic non-G12C KRAS mutations in KRAS G12C mutated lung adenocarcinomas in TRACERx and GENIE: A reservoir for intrinsic resistance to KRAS G12C inhibitors
    Marinelli, D.
    Pisegna, S.
    Giammaruco, M.
    Chesi, P.
    Mammone, G.
    Ceddia, S.
    Gazzaniga, P.
    Cortesi, E.
    Gelibter, A. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1345 - S1346
12345